Abstract 104P
Background
The proportion of oral and oropharyngeal squamous cell carcinoma (OOSCC) that can be attributed to human papillomavirus (HPV) infection is growing nowadays. A potential factor indicating the occurrence of HPV-positive OSCC is a change in the degree of methylation of gene promoters that play a key role in the immune response. In this study, we investigated the difference in methylation of bunch of gene promoters expected to be differently methylated in head and neck cancer versus healthy oral mucosa.
Methods
The presence of HPV infection in samples was examined earlier. To determine the difference in methylation of those gene promotors, isolated and bisulfite-modified DNA was analysed by Methylation Specific PCR method (MSP). The standard Chi-square test was used for the comparison of two groups of samples. Spearman’s correlation was used, and the Spearman’s rank correlation coefficient between groups’ data is calculated.
Results
The best potential biomarkers were EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12 gene promoters. They found to be more hypomethylated in the oral and oropharyngeal cancer samples in comparison to normal tissue. In samples of healthy oral mucosa, the investigated gene promoters were found to be methylated in a very high percentage, up to 100%, while in oral and oropharyngeal cancer samples, they were methylated in a very low percentage, about 20 %, regardless of HPV infection.
Conclusions
In conclusion, methylation of immune gene promoters may be good potential biomarker of head and neck cancer, primarily OOSCC, and possibly, indicator of prognosis and progression of individual OOSCC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The Ruđer Bošković Institute.
Funding
European Social Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract